JP2024524701A - ２－（３－（４－（１ｈ－インダゾール－５－イルアミノ）キナゾリン－２－イル）フェノキシ）－ｎ－イソプロピルアセトアミドメタンスルホン酸塩の固体形態 - Google Patents

２－（３－（４－（１ｈ－インダゾール－５－イルアミノ）キナゾリン－２－イル）フェノキシ）－ｎ－イソプロピルアセトアミドメタンスルホン酸塩の固体形態 Download PDF

Info

Publication number
JP2024524701A
JP2024524701A JP2024502063A JP2024502063A JP2024524701A JP 2024524701 A JP2024524701 A JP 2024524701A JP 2024502063 A JP2024502063 A JP 2024502063A JP 2024502063 A JP2024502063 A JP 2024502063A JP 2024524701 A JP2024524701 A JP 2024524701A
Authority
JP
Japan
Prior art keywords
belmosudil
mesylate
crystalline form
crystalline
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524701A5 (https=
Inventor
レンガウアー，ハンネス
マルグライター，レナーテ
ピヒラー，アルトゥール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JP2024524701A publication Critical patent/JP2024524701A/ja
Publication of JP2024524701A5 publication Critical patent/JP2024524701A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024502063A 2021-07-16 2022-07-18 ２－（３－（４－（１ｈ－インダゾール－５－イルアミノ）キナゾリン－２－イル）フェノキシ）－ｎ－イソプロピルアセトアミドメタンスルホン酸塩の固体形態 Pending JP2024524701A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21186105.9 2021-07-16
EP21186105 2021-07-16
EP21199739.0 2021-09-29
EP21199739 2021-09-29
PCT/EP2022/070063 WO2023285706A1 (en) 2021-07-16 2022-07-18 Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt

Publications (2)

Publication Number Publication Date
JP2024524701A true JP2024524701A (ja) 2024-07-05
JP2024524701A5 JP2024524701A5 (https=) 2025-07-28

Family

ID=82850759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502063A Pending JP2024524701A (ja) 2021-07-16 2022-07-18 ２－（３－（４－（１ｈ－インダゾール－５－イルアミノ）キナゾリン－２－イル）フェノキシ）－ｎ－イソプロピルアセトアミドメタンスルホン酸塩の固体形態

Country Status (4)

Country Link
US (1) US20240343712A1 (https=)
EP (1) EP4370205A1 (https=)
JP (1) JP2024524701A (https=)
WO (1) WO2023285706A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024100601A1 (en) 2022-11-11 2024-05-16 Assia Chemical Industries Ltd. Solid state forms of belumosudil and processes for preparation thereof
CN117603194A (zh) * 2023-10-30 2024-02-27 南京科默生物医药有限公司 一种甲磺酸贝舒地尔的晶型及其制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2008054599A2 (en) 2006-09-27 2008-05-08 Surface Logix, Inc. Rho kinase inhibitors
PL2903618T3 (pl) 2012-10-05 2022-09-19 Kadmon Corporation, Llc Inhibitory kinazy rho
JP2016502502A (ja) 2012-10-05 2016-01-28 カドモン コーポレイション，リミティド ライアビリティ カンパニー 眼疾患の治療
EP3875078A1 (en) * 2020-03-06 2021-09-08 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19
HRP20241789T1 (hr) * 2020-07-22 2025-03-14 Assia Chemical Industries Ltd. Čvrsti oblici belumosudila i soli belumosudila
WO2022170864A1 (zh) * 2021-02-09 2022-08-18 苏州科睿思制药有限公司 Belumosudil甲磺酸盐的晶型及其制备方法和用途

Also Published As

Publication number Publication date
EP4370205A1 (en) 2024-05-22
WO2023285706A1 (en) 2023-01-19
US20240343712A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
JP6603306B2 (ja) ドルテグラビルナトリウムの新規な水和物
EP3679017B1 (en) Co-crystal of an orally available hif prolyl hydroxylase inhibitor
US20240287066A1 (en) Crystalline Form of Sotorasib
EP3808742A1 (en) Polymorph of selinexor
EP3666776A1 (en) Hydrate of a gonadotropin-releasing hormone receptor antagonist
JP2024524701A (ja) ２－（３－（４－（１ｈ－インダゾール－５－イルアミノ）キナゾリン－２－イル）フェノキシ）－ｎ－イソプロピルアセトアミドメタンスルホン酸塩の固体形態
WO2022189599A1 (en) Crystalline forms of mavacamten for the treatment of hcm
TW202108581A (zh) N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
US10053427B2 (en) Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US12590095B2 (en) Crystalline forms of an orally available, selective kit and PDGFR kinase inhibitor
EP3887356B1 (en) Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
TW202241425A (zh) 用於製造二苯基吡𠯤衍生物之程序
EP4378942A1 (en) Crystal form of a pde3/4 inhibitor
WO2022069357A1 (en) Crystalline form of selpercatinib
WO2022117448A1 (en) Crystalline forms of pralsetinib
US20240327379A1 (en) Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
WO2021001457A1 (en) Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
EP4227305A1 (en) Crystalline form of sotorasib
EP4137133A1 (en) Crystalline form of avacopan
WO2023052652A1 (en) Crystalline form of acoramidis hydrochloride
WO2022263263A1 (en) Crystalline form of avacopan
WO2022013052A1 (en) Compounds comprising voxelotor and 2,5-dihydroxybenzoic acid and crystal forms
US20170369475A1 (en) Flibanserin Hydrate
HK40128634A (zh) 胺基喹唑啉衍生物的盐
WO2020187674A1 (en) Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428